Research
Hormonal
Metformin therapy improves menstrual function and ovulation rates in PCOS patients, with efficacy varying based on baseline testosterone levels and severity of menstrual irregularities.
Metformin is an effective medication for restoring regular periods and ovulation in many PCOS patients, working in 40-90% of cases. It is often used when lifestyle changes alone are insufficient or for fertility treatment. Discuss with your doctor if it's right for you, as it may cause stomach upset initially.
GoodQualifiesHIGH confidence
Metformin therapy has been shown to induce resumption of normal, ovulatory menstrual cycles in 40% to 90% of patients studied. Doses used varied from 500 to 1000 mg twice daily.
Why this rating
The paper cites multiple studies showing 40-90% ovulation rates, though it notes variability and lack of consensus on optimal duration.
Source
Polycystic Ovarian Syndrome: Diagnosis and Management
M. T. Sheehan · Clinical Medicine & Research · 2004
DOI 10.3121/cmr.2.1.13
narrative_reviewCited 265×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lifestyle modification and weight loss are the primary, constant interventions for managing insulin resistance and its associated long-term health risks in patients with Polycystic Ovarian Syndrome (PCOS).Good
- Oral contraceptives are the primary medical treatment for regulating menstrual cycles and treating hirsutism in PCOS, but they do not address the underlying insulin resistance and may worsen lipid profiles.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →